Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Fineline Cube Apr 28, 2026
Company Drug

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Fineline Cube Apr 28, 2026
Company Deals

Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy

Fineline Cube Nov 28, 2023

Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive...

Company Medical Device

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Fineline Cube Nov 28, 2023

Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...

Company R&D

XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization

Fineline Cube Nov 28, 2023

XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...

Company Drug

Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda

Fineline Cube Nov 28, 2023

Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...

Policy / Regulatory

China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings

Fineline Cube Nov 27, 2023

The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...

Company Deals

DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix

Fineline Cube Nov 27, 2023

South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to...

Company Deals

KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities

Fineline Cube Nov 27, 2023

KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...

Company Drug

Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China

Fineline Cube Nov 27, 2023

Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...

Company Drug

Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China

Fineline Cube Nov 27, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...

Company Drug

Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation

Fineline Cube Nov 27, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...

Company Medical Device

Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial

Fineline Cube Nov 27, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Company Deals

Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee

Fineline Cube Nov 27, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

Fineline Cube Nov 27, 2023

The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...

Company Drug

Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules

Fineline Cube Nov 27, 2023

Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...

Policy / Regulatory R&D

China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development

Fineline Cube Nov 27, 2023

China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...

Company Legal / IP

AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market

Fineline Cube Nov 27, 2023

AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...

Company Drug

Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia

Fineline Cube Nov 27, 2023

Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...

Posts pagination

1 … 430 431 432 … 658

Recent updates

  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
  • Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”
  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Company Drug

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Company Drug

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.